Short overview on metabolomic approach and redox changes in psychiatric disorders

Redox Biology

Volumn 14, Issue , 2018, Pages 178-186

  Nedic Erjavec, Gordana ^a,b   Konjevod, Marcela ^a   Nikolac Perkovic, Matea ^a   Svob Strac, Dubravka ^a   Tudor, Lucija ^a   Barbas, Coral ^b   Grune, Tilman ^c   Zarkovic, Neven ^a   Pivac, Nela ^a  

^a RUDER BO KOVI INSTITUTE   (Croatia)

^b UNIVERSIDAD SAN PABLO CEU   (Spain)

^c GERMAN INSTITUTE OF HUMAN NUTRITION   (Germany)

Author keywords

Biomarkers; Depression; Lipid peroxidation; Metabolomics; Oxidative stress; Posttraumatic stress disorder; Schizophrenia

Indexed keywords

4 HYDROXYNONENAL; ANTIDEPRESSANT AGENT; ANTIOXIDANT; LYSOPHOSPHOLIPID; MALONALDEHYDE; REACTIVE OXYGEN METABOLITE; BIOLOGICAL MARKER;

CELL METABOLISM; CHRONIC STRESS; DEPRESSION; DNA DAMAGE; HUMAN; INFLAMMATION; LIPID PEROXIDATION; MENTAL DISEASE; METABOLITE; METABOLOMICS; NEUROTOXICITY; NITROSATIVE STRESS; NONHUMAN; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PERSONALIZED MEDICINE; POSTTRAUMATIC STRESS DISORDER; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA; TREATMENT RESPONSE; METABOLISM; METABOLOME; PATHOLOGY;

BIOMARKERS; HUMANS; METABOLOME; METABOLOMICS; OXIDATION-REDUCTION; OXIDATIVE STRESS; SCHIZOPHRENIA; STRESS DISORDERS, POST-TRAUMATIC;

EID: 85029574710     PISSN: 22132317     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.redox.2017.09.002     Document Type: Review

References (114)

1. Anderson, G., Maes, M., Oxidative/nitrosative stress and immuno-inflammatory pathways in depression: treatment implications. Curr. Pharm. Des. 20 (2014), 3812–3847.
2. APA, Diagnostic and Statistical Manual of Mental Disorders (DSM-IV), 4th ed, 1994, American Psychiatric Association, Washington, DC (886 p.).
3. APA, Diagnostic and Statistical Manual of Mental Disorders (DSMV), 5th ed, 2013, American Psychiatric Association, Washington, DC (947 p.).
4. Asberg, M., Bertilsson, L., Mårtensson, B., Scalia-Tomba, G.P., Thorén, P., Träskman-Bendz, L., CSF monoamine metabolites in melancholia. Acta Psychiatr. Scand. 69 (1984), 201–219.
5. Beckonert, O., Keun, H.C., Ebbels, T.M.D., Bundy, J., Holmes, E., Lindon, J.C., et al. Metabolic profiling, metabolomic and metabonomic procedures for NMR spectroscopy of urine, plasma, serum and tissue extracts. Nat. Protoc. 2 (2007), 2692–2703.
6. Bisson, J.I., Post-traumatic stress disorder. Occup. Med-C. 57 (2007), 399–403.
7. Bitanihirwe, B.K.Y., Woo, T.U.W., Oxidative stress in schizophrenia: an integrated approach. Neurosci. Biobehav. Rev. 35 (2011), 878–893.
8. Bray, N.J., Leweke, F.M., Kapur, S., Meyer-Lindenberg, A., The neurobiology of schizophrenia: new leads and avenues for treatment. Curr. Opin. Neurobiol. 20 (2010), 810–815.
9. Brennan, L., NMR-based metabolomics: from sample preparation to applications in nutrition research. Prog. Nucl. Mag. Res. Spectrosc. 83 (2014), 42–49.
10. Britvic, D., Anticevic, V., Kaliterna, M., Lusic, L., Beg, A., Brajevic-Gizdic, I., et al. Comorbidities with Posttraumatic Stress Disorder (PTSD) among combat veterans: 15 years postwar analysis. Int. J. Clin. Health Psychol. 15 (2015), 81–92.
11. Cai, H.L., Li, H.D., Yan, X.Z., Sun, B., Zhang, Q., Yan, M., et al. Metabolomic analysis of biochemical changes in the plasma and urine of first-episode neuroleptic-naïve schizophrenia patients after treatment with risperidone. J. Proteome Res. 11 (2012), 4338–4350.
12. Ceprnja, M., Derek, L., Unic, A., Blazev, M., Fistonic, M., Kozaric-Kovacic, D., et al. Oxidative stress markers in patients with post-traumatic stress disorder. Coll. Antropol. 35 (2011), 1155–1160.
13. Cipak Gasparovic, A., Zarkovic, N., Zarkovic, K., Semen, K., Kaminskyy, K., Yelisyeyeva, O., Bottary, S.P., Biomarkers of Redox signalling, oxidative and nitro-oxidative stress: conventional and novel approaches. Br. J. Phamacol 174 (2017), 1771–1783.
14. Czarny, P., Wigner, P., Galecki, P., Sliwinski, T., The interplay between inflammation, oxidative stress, DNA damage, DNA repair and mitochondrial dysfunction in depression. Prog. Neuropsychopharmacol. Biol. Psychiatry, S0278–5846(16), 2017 (30298-6).
15. Dean, J., Keshavan, M., The neurobiology of depression: an integrated view. Asian J. Psychiatrry 27 (2017), 101–111.
16. Domschke, K., Patho-genetics of posttraumatic stress disorder. Psychiatr. Danub. 24 (2012), 267–273.
17. Dunn, W.B., Broadhurst, D., Ellis, D.I., Brown, M., Halsall, A., O'Hagan, S., et al. A GC-TOF-MS study of the stability of serum and urine metabolomes during the UK Biobank sample collection and preparation protocols. Int. J. Epidemiol. 37 (2008), 23–30.
18. Egea, J., Fabregat, I., Frapart, Y.M., Ghezzi, P., Görlach, A., et al. European contribution to the study of ROS: a summary of the findings and prospects for the future from the COST action BM1203 (EU-ROS). Redox Biol. 13 (2017), 94–162.
19. Elrayess, M.A., Almuraikhy, S., Kafienah, W., Al-Menhali, A., Alkhelaifi, F., Bashah, M., Zarkovic, K., Zarkovic, N., Waeg, G., Alsayrafi, M., Jaganjac, M., 4-Hydroxynonenal causes impairment of human subcutaneous adipogenesis and induction of adipocyte insulin resistance. Free Radic. Biol. Med. 104 (2017), 129–137.
20. Emiliani, F.E., Sedlak, T.W., Sawa, A., Oxidative stress and schizophrenia: recent breakthroughs from an old story. Curr. Opin. Psychiatry 27 (2014), 185–190.
21. Fedorova, M., Zarkovic, N., Preface to the special issue on 4-Hydroxynonenal and related lipid oxidation products. Free Radic. Biol. Med., 111, 2017, 1.
22. Fiehn, O., Metabolomics – the link between genotypes and phenotypes. Plant Mol. Biol. 48 (2002), 155–171.
23. Frijhoff, J., Winyard, P.G., Zarkovic, N., Davies, S., et al. Clinical relevance of biomarkers of oxidative stress. Antioxid. Redox Signal 23 (2015), 1144–1170.
24. Garcia-Alvarez, L., Paz Garcia-Portilla, M., Gonzalez-Blanco, L., Saiz Martinez, P.A., de la Fuente-Tomas, L., Menendez-Miranda, I., et al. Differential blood-based biomarkers of psychopathological dimensions of schizophrenia. Rev. Psiquiatr. Salud Ment. 9 (2016), 219–227.
25. Gęgotek, A., Nikliński, J., Zarkovic, N., Zarkovic, K., Waeg, G., Łuczaj, W., Charkiewicz, R., Skrzydlewska, E., Lipid mediators involved in the oxidative stress and antioxidant defence of human lung cancer cells. Redox Biol. 9 (2016), 210–219.
26. German, J.B., Hammock, B.D., Watkins, S.M., Metabolomics: building on a century of biochemistry to guide human health. Metabolomics 1 (2005), 3–9.
27. Go, E.P., Database resources in metabolomics: an overview. J. Neuroimmune Pharmacol. 5 (2010), 18–30.
28. Gola, H., Engler, H., Sommershof, A., Adenauer, H., Kolassa, S., Schedlowski, M., et al. Posttraumatic stress disorder is associated with an enhanced spontaneous production of pro-inflammatory cytokines by peripheral blood mononuclear cells. BMC Psychiatry, 13, 2013, 40.
29. Gonzalez-Blanco, L., Garcia-Portilla, M.P., Garcia-Alvarez, L., Iglesias, C., Saiz, P., Coto, A., et al. Inflammatory and metabolic biomarkers of psychopathological dimensions of schizophrenia. Eur. Psychiatry, 33, 2016, 250.
30. Greenberg, M.S., Tanev, K., Marin, M.F., Pitman, R.K., Stress, PTSD, and dementia. Alzheimers Dement 10 (2014), 155–165.
31. Hauer, D., Schelling, G., Gola, H., Campolongo, P., Morath, J., Roozendaal, B., et al. Plasma concentrations of endocannabinoids and related primary fatty acid amides in patients with post-traumatic stress disorder. PLoS ONE, 8, 2013, 62741.
32. He, Y., Yu, Z., Giegling, I., Xie, L., Hartmann, A.M., Prehn, C., et al. Schizophrenia shows a unique metabolomics signature in plasma. Transl. Psychiat, 2, 2012, 149.
33. Hill, M.N., Bierer, L.M., Makotkine, I., Golier, J.A., Galea, S., McEwen, B.S., et al. Reductions in circulating endocannabinoid levels in individuals with post-traumatic stress disorder following exposure to the world trade center attacks. Psychoneuroendocrinology 38 (2013), 2952–2961.
34. Holmes, E., Wilson, I.D., Nicholson, J.K., Metabolic phenotyping in health and disease. Cell 134 (2008), 714–717.
35. Hovatta, I., Juhila, J., Donner, J., Oxidative stress in anxiety and comorbid disorders. Neurosci. Res. 68 (2010), 261–275.
36. Jaganjac, M., Almuraikhy, S., Al-Khelaifi, M., Al-Jaber, M., Bashah, M., Mazloum, N.A., Zarkovic, K., Zarkovic, N., Waeg, G., Kafienah, W., Combined metformin and insulin treatment reverses metabolically impaired omental adipogenesis and accumulation of 4-hydroxynonenal in obese diabetic patients. Redox Biol. 12 (2017), 483–490.
37. Kaal, E., Janssen, H.G., Extending the molecular application range of gas chromatography. J. Chromatogr. A 1184 (2008), 43–60.
38. Kaddurah-Daouk, R., Yuan, P., Boyle, S.H., Matson, W., Wang, Z., Zeng, Z.B., et al. Cerebrospinal fluid metabolome in mood disorders-remission state has a unique metabolic profile. Sci. Rep., 2, 2012, 667.
39. Kanehisa, M., Goto, S., Sato, Y., Kawashima, M., Furumichi, M., Tanabe, M., Data, information, knowledge and principle: back to metabolism in KEGG. Nucleic Acids Res. 42 (2014), 199–205.
40. Kao, C.Y., Anderzhanova, E., Asara, J.M., Wotjak, C.T., Turck, C.W., NextGen brain microdialysis: applying modern metabolomics technology to the analysis of extracellular fluid in the central nervous system. Mol. Neuropsychiatry 1 (2015), 60–67.
41. Kao, C.Y., Pathway and Biomarker Discovery in a Posttraumatic Stress Disorder Mouse Model (Doctoral disertation). 2015, Graduate School of Systemic Neurosciences der Ludwig-Maximilians-Universität München, Munich, Germany.
42. Karabatsiakis, A., Hamuni, G., Wilker, S., Kolassa, S., Renu, D., Kadereit, S., et al. Metabolite profiling in posttraumatic stress disorder. J. Mol. Psychiatry 3 (2015), 1–11.
43. Kasture, V.S., Musmade, D.S., Vakte, M.B., Sonawane, S.B., Patil, P.P., Metabolomics: current technologies and future trends. Int J. Res Dev. Pharm. Life Sci. 2 (2012-13), 206–217.
44. Kemp, G., Capillary electrophoresis. Biotechnol. Appl. Biochem. 27 (1998), 9–17.
45. Kilpatrick, D.G., Resnick, H.S., Milanak, M.E., Miller, M.W., Keyes, K.M., Friedman, M.J., National estimates of exposure to traumatic events and PTSD prevalence using DSM-IV and DSM-V criteria. J. Trauma Stress 26 (2013), 537–547.
46. Kind, T., Wohlgemuth, G., Lee, D.Y., Lu, Y., Palazoglu, M., Shahbaz, S., et al. FiehnLib: mass spectral and retention index libraries for metabolomics based on quadrupole and time-of-flight gas chromatography/mass spectrometry. Anal. Chem. 81 (2009), 10038–10048.
47. Klinedinst, N.J., Regenold, W.T., A mitochondrial bioenergetic basis of depression. J. Bioenergy Biomembr. 47 (2015), 155–171.
48. Liu, J., Litt, L., Segal, M.R., Kelly, M.J.S., Pelton, J.G., Kim, M., Metabolomics of oxidative stress in recent studies of endogenous and exogenously administered intermediate metabolites. Int. J. Mol. Sci. 12 (2011), 6469–6501.
49. Liu, X., Zheng, P., Zhao, X., Zhang, Y., Hu, C., Li, J., Zhao, J., Zhou, J., Xie, P., Xu, G., Discovery and validation of plasma biomarkers for major depressive disorder classification based on liquid chromatography-mass spectrometry. J. Proteome Res. 14 (2015), 2322–2330.
50. Łuczaj, W., Moniuszko, A., Jarocka-Karpowicz, I., Pancewicz, S., Andrisic, L., Zarkovic, N., Skrzydlewska, E., Tick-borne encephalitis - lipid peroxidation and its consequences. Scand. J. Clin. Lab Investig. 28 (2016), 1–9.
51. Łuczaj, W., Gindzienska-Sieskiewicz, E., Jarocka-Karpowicz, I., Andrisic, L., Sierakowski, S., Zarkovic, N., Waeg, G., Skrzydlewska, E., The onset of lipid peroxidation in rheumatoid arthritis: consequences and monitoring. Free Radic. Res. 50 (2016), 304–313.
52. Martins-de-Souza, D., Proteomics, metabolomics, and protein interactomics in the characterization of the molecular features of major depressive disorder. Dialog. Clin. Neurosci. 16 (2014), 63–73.
53. Mastrangelo, A., Ferrarini, A., Rey-Stolle, F., Garcia, A., Barbas, C., From sample treatment to biomarker discovery: a tutorial for untargeted metabolomics based on GC-(EI)-Q-MS. Anal. Chim. Acta 900 (2015), 21–35.
54. Maurya, P.K., Noto, C., Rizzo, L.B., Rios, A.C., Nunes, S.O., Barbosa, D.S., et al. The role of oxidative and nitrosative stress in accelerated aging and major depressive disorder. Prog. Neuropsychopharmacol. Biol. Psychiatry 65 (2016), 134–144.
55. Mertsch, K., Blasig, I., Grune, T., 4-Hydroxynonenal impairs the permeability of an in vitro rat blood–brain barrier. Neurosci. Lett. 314 (2001), 135–138.
56. Michopoulos, V., Norrholm, S.D., Jovanovic, T., Diagnostic biomarkers for posttraumatic stressdisorder: promising horizons from translational neuroscience research. Biol. Psychiatry 78 (2015), 344–353.
57. Miller, M.W., Sadeh, N., Traumatic stress, oxidative stress and post-traumatic stress disorder: neurodegeneration and the accelerated-aging hypothesis. Mol. Psychiatry 19 (2014), 1156–1162.
58. Moniuszko-Malinowska, A., Łuczaj, W., Jarocka-Karpowicz, I., Pancewicz, S., Zajkowska, J., Andrisic, L., Zarkovic, N., Skrzydlewska, E., Lipid peroxidation in the pathogenesis of neuroborreliosis. Free Radic. Biol. Med. 96 (2016), 255–263.
59. Moon, M.L., Joesting, J.J., Lawson, M.A., Chiu, G.S., Blevins, N.A., Kwakwa, K.A., et al. The saturated fatty acid, palmitic acid, induces anxiety-like behavior in mice. Metabolism 63 (2014), 1131–1140.
60. Moreno, F.A., Parkinson, D., Palmer, C., Castro, W.L., Misiaszek, J., El Khoury, A., et al. CSF neurochemicals during tryptophan depletion in individuals with remitted depression and healthy controls. Eur. Neuropsychopharmacol. 20 (2010), 18–24.
61. Moreno-Villanueva, M., Morath, J., Vanhooren, V., Elbert, T., Kolassa, S., Libert, C., et al. N-glycosylation profiling of plasma provides evidence for accelerated physiological aging in post-traumatic stress disorder. Transl. Psychiatry, 3, 2013, 320.
62. Naz, S., Garcia, A., Barbas, C., Multiplatform analytical methodology for metabolic fingerprinting of lung tissue. Anal. Chem. 85 (2013), 10941–10948.
63. Naz, S., Moreira dos Santos, D.C., García, A., Barbas, C., Analytical protocols based on LC-MS, GC-MS and CE-MS for nontargeted metabolomics of biological tissues. Bioanalysis 6 (2014), 1657–1677.
64. Neumeister, A., Normandin, M.D., Pietrzak, R.H., Piomelli, D., Zheng, M.Q., Gujarro-Anton, A., et al. Elevated brain cannabinoid CB1 receptor availability in post-traumatic stress disorder: a positron emission tomography study. Mol. Psychiatry 18 (2013), 1034–1040.
65. Neylan, T.C., Schadt, E.E., Yehuda, R., Biomarkers for combat-related PTSD: focus on molecular networks from high-dimensional data. Eur. J. Psychotraumatol., 5, 2014, 23938.
66. Ng, F., Berk, M., Dean, O., Bush, A.I., Oxidative stress in psychiatric disorders: evidence base and therapeutic implications. Int. J. Neuropsychopharmacol. 11 (2008), 851–876.
67. Nikolac Perkovic, M., Nedic Erjavec, G., Svob Strac, D., Uzun, S., Kozumplik, O., Pivac, N., Theranostic biomarkers for schizophrenia. Int. J. Mol. Sci., 18, 2017, 733.
68. Noctor, G., Lelarge-Trouverie, C., Mhamdi, A., The metabolomics of oxidative stress. Phytochemistry 112 (2015), 33–53.
69. Nunes, A.F., Amaral, J.D., Lo, A.C., Fonseca, M.B., Viana, R.J., Callaerts-Vegh, Z., et al. TUDCA, a bile acid, attenuates amyloid precursor protein processing and amyloid-β deposition in APP/PS1 mice. Mol. Neurobiol. 45 (2012), 440–454.
70. O'Dushlaine, C., Rossin, L., Lee, P.H., Duncan, L., Parikshak, N.N., Newhouse, S., et al. Psychiatric genome-wide association study analyses implicate neuronal, immune and histone pathways. Nat. Neurosci. 18 (2015), 199–209.
71. Oresic, M., Tang, J., Seppänen-Laakso, T., Mattila, I., Saarni, S.E., Saarni, S.I., et al. Metabolome in schizophrenia and other psychotic disorders: a general population-based study. Genome Med., 3, 2011, 19.
72. Pace, T.W., Heim, C.M., A short review on the psychoneuroimmunology of posttraumatic stress disorder: from risk factors to medical comorbidities. Brain Behav. Immun. 25 (2011), 6–13.
73. Park, H.R., Kim, J.Y., Park, K.Y., Lee, J., Lipotoxicity of palmitic acid on neural progenitor cells and hippocampal neurogenesis. Toxicol. Res. 27 (2011), 103–110.
74. Pasikanti, K.K., Ho, P.C., Chan, E.C.Y., Gas chromatography/mass spectrometry in metabolic profiling of biological fluids. J. Chromatogr. B 871 (2008), 202–211.
75. Pejchinovski, M., Klein, J., Ramírez-Torres, A., Bitsika, V., Mermelekas, G., Vlahou, A., et al. Comparison of higher energy collisional dissociation and collision-induced dissociationMS/MS sequencing methods for identification of naturally occurring peptides in human urine. Proteom. Clin. Appl. 9 (2015), 531–542.
76. Petrovchich, I., Sosinsky, A., Konde, A., Archibald, A., Henderson, D., Maletic-Savatic, M., et al. Metabolomics in schizophrenia and major depressive disorder. Front Biol. 11 (2016), 222–231.
77. Piskac Zivkovic, N., Petrovecki, M., Tomasovic Loncaric, C., Nikolic, I., Waeg, G., Jaganjac, M., Zarkovic, K., Zarkovic, N., Positron emission tomography-computed tomography and 4-hydroxynonenal-histidine immunohistochemistry reveal differential onset of lipid peroxidation in primary lung cancer and in pulmonary metastasis of remote malignancies. Redox Biol. 11 (2017), 600–605.
78. Pitman, R.K., Rasmusson, A.M., Koenen, K.C., Shin, L.M., Orr, S.P., Gilbertson, M.W., et al. Biological studies of post-traumatic stress disorder. Nat. Rev. Neurosci. 13 (2012), 769–787.
79. Poli, G., Zarkovic, N., Editorial introduction to the special issue on 4-hydroxynonenal and related lipid oxidation products. Free Radic. Biol. Med. 111 (2017), 2–5.
80. Pontes, J.G.M., Brasil, A.J.M., Cruz, G.C.F., deSouza, R.N., Tasic, L.J., NMR-based metabolomics strategies: plants, animals and humans. Anal. Methods 9 (2016), 1078–1096.
81. Priebe, S., Bogic, M., Ajdukovic, D., Franciskovic, T., Galeazzi, G.M., Kucukalic, A., et al. Mental disorders following war in the Balkans: a study in 5 countries. Arch. Gen. Psychiatry 67 (2010), 518–528.
82. Quinones, M.P., Kaddurah-Daouk, R., Metabolomics tools for identifying biomarkers for neuropsychiatric diseases. Neurobiol. Dis. 35 (2009), 165–176.
83. Roessner, U., Bowne, J., What is metabolomics all about?. Biotechniques 46 (2009), 363–365.
84. Rojo, A.I., McBean, G., Cindric, M., Egea, J., López, M.G., Rada, P., Zarkovic, N., Cuadrado, A., Redox control of microglial function: molecular mechanisms and functional significance. Antioxid. Redox Signal. 21 (2014), 1766–1801.
85. Romano, A., Serviddio, G., Calcagnini, S., Villani, R., Giudetti, A.M., Cassano, T., Gaetani, S., Linking lipid peroxidation and neuropsychiatric disorders: focus on 4-hydroxy-2-nonenal. Free Radic. Biol. Med. 111 (2017), 281–293.
86. Santos-Soto, I.J., Chorna, N., Carballeira, N.M., Vélez-Bartolomei, J.G., Méndez-Merced, A.T., Chornyy, A.P., et al. Voluntary running in young adult mice reduces anxiety-like behavior and increases the accumulation of bioactive lipids in the cerebral cortex. PLoS ONE, 8, 2013, 81459.
87. Schmidt, U., Holsboer, F., Rein, T., Epigenetic aspects of posttraumatic stress disorder. Dis. Markers 30 (2011), 77–87.
88. Schuff, N., Neylan, T.C., Lenoci, M.A., Du, A.T., Weiss, D.S., Marmar, C.R., et al. Decreased hippocampal N-acetylaspartate in the absence of atrophy in posttraumatic stress disorder. Biol. Psychiatry 50 (2001), 952–959.
89. Sies, H., Hydrogen peroxide as a central redox signaling molecule in physiological oxidative stress: oxidative eustress. Redox Biol. 11 (2017), 613–619.
90. Smoller, J.W., The genetics of stress-related disorders: PTSD, depression, and anxiety disorders. Neuropsychopharmacology 41 (2016), 297–319.
91. Sparkman, O.D., Penton, Z.E., Kitson, F.G., Gas Chromatography and Mass Spectrometry: a Practical Guide. 2nd ed., 2011, Academic Press, Cambridge Massachusetts, USA, 632.
92. Sumner, L.W., Amberg, A., Barrett, D., Beale, M.H., Beger, R., Daykin, C.A., et al. Proposed minimum reporting standards for chemical analysis. Metabolomics 3 (2007), 211–221.
93. Tezcan, E., Atmaca, M., Kuloglu, M., Ustundag, B., Free radicals in patients with post-traumatic stress disorder. Eur. Arch. Psychiatry Clin. Neurosci. 253 (2003), 89–91.
94. Vaz, A.R., Cunha, C., Gomes, C., Schmucki, N., Barbosa, M., Brites, D., Glycoursodeoxycholic acid reduces matrix metalloproteinase-9 and caspase-9 activation in a cellular model of superoxide dismutase-1 neurodegeneration. Mol. Neurobiol. 51 (2015), 864–877.
95. Wang, S.M., Han, C., Lee, S.J., Patkar, A.A., Masand, P., Pae, C.U., A review of current evidence for acetyl-l-carnitine in the treatment of depression. J. Psychiatr. Res. 53 (2014), 30–37.
96. Wang, Z.J., Li, G.M., Tang, W.L., Yin, M., Neuroprotective effects of stearic acid against toxicity of oxygen/glucose deprivation or glutamate on rat cortical or hippocampal slices. Acta Pharmacol. Sin. 27 (2006), 145–150.
97. Weber, D., Milkovic, L., Bennett, S.J., Griffiths, H.R., Zarkovic, N., Grune, T., Measurement of HNE protein adducts in human plasma and serum by ELISA - Comparison of two primary antibodies. Redox Biol. 1 (2013), 226–233.
98. Westerhuis, J.A., Hoefsloot, H.C.J., Smit, S., Vis, D.J., Smilde, A.K., van Velzen, E.J.J., et al. Assessment of PLSDA cross validation. Metabolomics 4 (2008), 81–89.
99. Wishart, D.S., Tzur, D., Knox, C., Eisner, R., Guo, A.C., Young, N., et al. HMDB: the human metabolome database. Nucleic Acids Res. 35 (2007), 521–526.
100. Woo, H.I., Chun, M.R., Yang, J.S., Lim, S.W., Kim, M.J., Kim, S.W., et al. Plasma amino acid profiling in major depressive disorder treated with selective serotonin reuptake inhibitors. CNS Neurosci. Ther. 21 (2015), 417–424.
101. Wood, P.L., Mass spectrometry strategies for clinical metabolomics and lipidomics in psychiatry, neurology, and neuro-oncology. Neuropsychopharmacology 39 (2014), 24–33.
102. Worley, B., Powers, R., Multivariate analysis in metabolomics. Curr. Metabol. 1 (2013), 92–107.
103. Yang, J., Chen, T., Sun, L., Zhao, Z., Qi, X., Zhou, K., et al. Potential metabolite markers of schizophrenia. Mol. Psychiatry 18 (2013), 67–78.
104. Zarkovic, K., Jakovcevic, A., Zarkovic, N., Contribution of the HNE-immunohistochemistry to modern pathological concepts of major human diseases. Free Radic. Biol. Med. 111 (2017), 110–126.
105. Zarkovic, N., Zarkovic, K., Schaur, R.J., Štolc, S., Schlag, G., Redl, H., Waeg, G., Borovic, S., et al. 4-Hydroxynonenal as a second messenger of free radicals and growth modifying factor. Life Sci. 65 (1999), 1901–1904.
106. Zhang, A., Sun, H., Wang, X., Serum metabolomics as a novel diagnostic approach for disease: a systematic review. Anal. Bioanal. Chem. 404 (2012), 1239–1245.
107. Zhang, L., Li, H., Benedek, D., Li, X., Ursano, R., A strategy for the development of biomarker tests for PTSD. Med. Hypotheses 73 (2009), 404–409.
108. Zhang, X.Y., Yao, J.K., Oxidative stress and therapeutic implications in psychiatric disorders. Prog. Neuro-Psychophopharmacol Biol. Psychiatry 46 (2013), 197–199.
109. Zheng, P., Chen, J.J., Huang, T., Wang, M.J., Wang, Y., Dong, M.X., et al. A novel urinary metabolite signature for diagnosing major depressive disorder. J. Proteome Res. 12 (2013), 5904–5911.
110. Zheng, P., Fang, Z., Xu, X.J., Liu, M.L., Du, X., Zhang, X., et al. Metabolite signature for diagnosing major depressive disorder in peripheral blood mononuclear cells. J. Affect. Disord. 195 (2016), 75–81.
111. Zheng, P., Gao, H.C., Li, Q., Shao, W.H., Zhang, M.L., Cheng, K., et al. Plasma metabonomics as a novel diagnostic approach for major depressive disorder. J. Proteome Res. 11 (2012), 1741–1748.
112. Zheng, P., Wang, Y., Chen, L., Yang, D., Meng, H., Zhou, D., et al. Identification and validation of urinary metabolite biomarkers for major depressive disorder. Mol. Cell Proteom. 12 (2013), 207–214.
113. Zhou, B., Xiao, J.F., Tulia, L., Ressom, H.W., LC-MS-based metabolomics. Mol. Biosyst. 8 (2012), 470–481.
114. Zoladz, P.R., Diamond, D.M., Current status on behavioral and biological markers of PTSD: a search for clarity in a conflicting literature. Neurosci. Biobehav. 37 (2013), 860–895.